AGP Executive Report
Last update: 11 hours agoUS Pharma Tariff Relief: The US Commerce Department says certain specialty medicines and ingredients from India and 19 other jurisdictions will face a 0% ad valorem tariff under the Section 232 framework, covering orphan drugs, fertility treatments, cell and gene therapies, antibody-drug conjugates, nuclear medicines, plasma-derived therapies, and related components—while the broader 100% tariff on other patented pharma imports still moves ahead. Liechtenstein in the Mix: Liechtenstein is explicitly listed among the eligible jurisdictions for the zero-tariff treatment, meaning qualifying shipments could avoid the steepest import duties. EU Childhood Treatment Update: Neuraxpharm and Minoryx report the European Commission granted marketing authorisation for Nezglyal for childhood cerebral adrenoleukodystrophy (cALD), described as the first EU pharmacological option for early intervention in ages 2–12. Health Policy & Access: The European Evangelical Alliance raises concerns about abortion law liberalisation efforts in Andorra and Liechtenstein, including a Liechtenstein parliament vote backing a citizen-led proposal for abortion access in the first 12 weeks. Healthcare Staffing: Ireland is relaxing the “50:50 rule” limiting non-EEA workers to tackle healthcare staff shortages, with nursing homes and home-care highlighted as under pressure.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
